These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 24840562

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study.
    Jahnz-Różyk K, Szepiel P.
    Int J Chron Obstruct Pulmon Dis; 2015; 10():613-23. PubMed ID: 25834420
    [Abstract] [Full Text] [Related]

  • 4. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.
    Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
    Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1425-34. PubMed ID: 27418815
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe.
    Fležar M, Jahnz-Różyk K, Enache G, Martynenko T, Kristufek P, Škrinjarić-Cincar S, Kadlecová P, Martinovic G.
    Int J Chron Obstruct Pulmon Dis; 2013; 8():483-92. PubMed ID: 24159258
    [Abstract] [Full Text] [Related]

  • 10. Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis.
    Konstan MW, Sharma A, Moroni-Zentgraf P, Wang F, Koker P.
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):137-44. PubMed ID: 25380193
    [Abstract] [Full Text] [Related]

  • 11. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.
    Cazzola M, Rogliani P, Ora J, Matera MG.
    Expert Rev Clin Pharmacol; 2015 Apr; 8(5):529-39. PubMed ID: 26294073
    [Abstract] [Full Text] [Related]

  • 12. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial.
    Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A.
    Int J Chron Obstruct Pulmon Dis; 2018 Apr; 13():605-616. PubMed ID: 29497289
    [Abstract] [Full Text] [Related]

  • 13. Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related.
    Koehorst-Ter Huurne K, Kort S, van der Palen J, van Beurden WJ, Movig KL, van der Valk P, Brusse-Keizer M.
    Int J Chron Obstruct Pulmon Dis; 2016 Apr; 11():1679-88. PubMed ID: 27555758
    [Abstract] [Full Text] [Related]

  • 14. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, Sigmund R, Hamelmann E, Engel M, Szefler S.
    Respir Res; 2015 Feb 07; 16(1):20. PubMed ID: 25851298
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
    Abrahams R, Moroni-Zentgraf P, Ramsdell J, Schmidt H, Joseph E, Karpel J.
    Respir Med; 2013 Jun 07; 107(6):854-62. PubMed ID: 23490224
    [Abstract] [Full Text] [Related]

  • 16. Anticholinergics aggravate the imbalance of the autonomic nervous system in stable chronic obstructive pulmonary disease.
    Yuan W, Nie S, Wang H, Xu Q, Jia N.
    BMC Pulm Med; 2019 May 09; 19(1):88. PubMed ID: 31072407
    [Abstract] [Full Text] [Related]

  • 17. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD.
    Hodder R, Pavia D, Lee A, Bateman E.
    Int J Chron Obstruct Pulmon Dis; 2011 May 09; 6():245-51. PubMed ID: 21814460
    [Abstract] [Full Text] [Related]

  • 18. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
    Tashkin DP.
    Expert Rev Respir Med; 2010 Jun 09; 4(3):279-89. PubMed ID: 20524910
    [Abstract] [Full Text] [Related]

  • 19. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun 09; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 20. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.
    Rau-Berger H, Mitfessel H, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2010 Oct 10; 5():367-73. PubMed ID: 21103403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.